| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8680613 | Alzheimer's & Dementia: Translational Research & Clinical Interventions | 2017 | 13 Pages |
Abstract
Repeated CAD106 administration was generally well tolerated. CAD106 450 μg with alum adjuvant demonstrated the best balance between antibody response and tolerability.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Rik Vandenberghe, Marie-Emmanuelle Riviere, Angelika Caputo, Judit Sovago, R. Paul Maguire, Martin Farlow, Giovanni Marotta, Raquel Sanchez-Valle, Philip Scheltens, J. Michael Ryan, Ana Graf,